Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

408 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-world outcomes with durvalumab after chemoradiotherapy in patients with unresectable stage III NSCLC: interim analysis of overall survival from PACIFIC-R.
Filippi AR, Bar J, Chouaid C, Christoph DC, Field JK, Fietkau R, Garassino MC, Garrido P, Haakensen VD, Kao S, Markman B, McDonald F, Mornex F, Moskovitz M, Peters S, Sibille A, Siva S, van den Heuvel M, Vercauter P, Anand S, Chander P, Licour M, de Lima AR, Qiao Y, Girard N. Filippi AR, et al. Among authors: chouaid c. ESMO Open. 2024 Jun;9(6):103464. doi: 10.1016/j.esmoop.2024.103464. Epub 2024 Jun 3. ESMO Open. 2024. PMID: 38833971 Free PMC article.
Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study.
Girard N, Bar J, Garrido P, Garassino MC, McDonald F, Mornex F, Filippi AR, Smit HJM, Peters S, Field JK, Christoph DC, Sibille A, Fietkau R, Haakensen VD, Chouaid C, Markman B, Hiltermann TJN, Taus A, Sawyer W, Allen A, Chander P, Licour M, Solomon B. Girard N, et al. Among authors: chouaid c. J Thorac Oncol. 2023 Feb;18(2):181-193. doi: 10.1016/j.jtho.2022.10.003. Epub 2022 Oct 25. J Thorac Oncol. 2023. PMID: 36307040 Free article.
Real-World Outcomes of Pralsetinib in RET Fusion-Positive NSCLC.
Lucibello F, Gounant V, Aldea M, Duruisseaux M, Perol M, Chouaid C, Bennouna J, Fallet V, Renault A, Guisier F, Giroux-Leprieur E, Wislez M, Toffart AC, Mazieres J, Basse C, Hegarat N, Carton M, Girard N. Lucibello F, et al. Among authors: chouaid c. JTO Clin Res Rep. 2024 Oct 17;6(1):100743. doi: 10.1016/j.jtocrr.2024.100743. eCollection 2025 Jan. JTO Clin Res Rep. 2024. PMID: 39850629 Free PMC article.
Prognostic value of comorbidities in older patients with cancer: the ELCAPA cohort study.
Benderra MA, Serrano AG, Paillaud E, Tapia CM, Cudennec T, Chouaïd C, Lorisson E, de la Taille A, Laurent M, Brain E, Bringuier M, Gligorov J, Caillet P, Canoui-Poitrïne F. Benderra MA, et al. Among authors: chouaid c. ESMO Open. 2023 Oct;8(5):101831. doi: 10.1016/j.esmoop.2023.101831. Epub 2023 Oct 11. ESMO Open. 2023. PMID: 37832389 Free PMC article.
SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer.
Borghaei H, de Marinis F, Dumoulin D, Reynolds C, Theelen WSME, Percent I, Gutierrez Calderon V, Johnson ML, Madroszyk-Flandin A, Garon EB, He K, Planchard D, Reck M, Popat S, Herbst RS, Leal TA, Shazer RL, Yan X, Harrigan R, Peters S; SAPPHIRE Investigators. Borghaei H, et al. Ann Oncol. 2024 Jan;35(1):66-76. doi: 10.1016/j.annonc.2023.10.004. Epub 2023 Oct 20. Ann Oncol. 2024. PMID: 37866811 Free article. Clinical Trial.
Real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: the REMIX study.
Macro M, Hulin C, Vincent L, Charvet-Rumpler A, Benboubker L, Calmettes C, Stoppa AM, Laribi K, Clement-Filliatre L, Zerazhi H, Honeyman F, Richez V, Maloisel F, Karlin L, Barrak J, Chouaid C, Leleu X. Macro M, et al. Among authors: chouaid c. Ann Hematol. 2023 Aug;102(8):2137-2151. doi: 10.1007/s00277-023-05278-3. Epub 2023 Jun 10. Ann Hematol. 2023. PMID: 37301786 Free PMC article.
408 results